Methyltransferase‐Like Protein 14 Attenuates Mitochondrial Antiviral Signaling Protein Expression to Negatively Regulate Antiviral Immunity via N6‐methyladenosine Modification
Source abstract
Abstract
Abstract Mitochondrial antiviral signaling (MAVS) protein is the core signaling adaptor in the RNA signaling pathway. Thus, appropriate regulation of MAVS expression is essential for antiviral immunity against RNA virus infection. However, the regulation of MAVS expression at the mRNA level especially at the post transcriptional level is not well‐defined. Here, it is reported that the MAVS mRNA undergoes N6‐methyladenosine (m6A) modification through methyltransferase‐like protein 14 (METTL14), which leads to a fast turnover of MAVS mRNA. Knockdown or deficiency of METTL14 increases MAVS mRNA stability, and downstream phosphorylation of TBK1/IRF3 and interferon‐β production in response to RNA viruses. Compared to wild‐type mice, heterozygotes Mettl14+/− mice better tolerate RNA virus infection. The authors' findings unveil a novel mechanism to regulate the stability of MAVS transcripts post‐transcriptionally through m6A modification.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA modifications and cancer · RNA Research and Splicing · Cancer-related molecular mechanisms research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Infection and Immunity of Shandong Province and Department of Immunology School of Biomedical Sciences Shandong University Jinan Shandong 250012 P. R. China
Funding
National Natural Science Foundation of China · National Postdoctoral Program for Innovative Talents · Natural Science Foundation of Shandong Province
References (30)
Show source-provided references
1. 10.1016/j.cell.2006.02.01510.1016/j.cell.2006.02.015 ↗
2. 10.1128/JVI.01635-1010.1128/JVI.01635-10 ↗
3. 10.1007/s11262-010-0544-x10.1007/s11262-010-0544-x ↗
4. Zhao X. · J. Infect. Dis. · 2020 · 221 · 647
5. 10.1073/pnas.121355910910.1073/pnas.1213559109 ↗
6. 10.1016/j.coviro.2015.04.00410.1016/j.coviro.2015.04.004 ↗
7. 10.1126/science.aaa263010.1126/science.aaa2630 ↗
8. 10.1038/ni.364110.1038/ni.3641 ↗
9. 10.1016/j.chom.2018.11.00110.1016/j.chom.2018.11.001 ↗
10. 10.15252/embj.201910328510.15252/embj.2019103285 ↗
11. 10.1186/s12866-018-1366-610.1186/s12866-018-1366-6 ↗
12. 10.1016/j.bbagrm.2018.10.01710.1016/j.bbagrm.2018.10.017 ↗
13. 10.1038/nrm.2016.13210.1038/nrm.2016.132 ↗
14. 10.1016/j.cell.2017.05.04510.1016/j.cell.2017.05.045 ↗
15. 10.1126/science.aau164610.1126/science.aau1646 ↗
16. 10.1016/j.cell.2014.08.00510.1016/j.cell.2014.08.005 ↗
17. 10.1038/nature2388310.1038/nature23883 ↗
18. 10.3390/ijms2006132310.3390/ijms20061323 ↗
19. 10.1073/pnas.141274211110.1073/pnas.1412742111 ↗
20. Winkler R. · Nat. Immunol. · 2019 · 20 · 17
21. 10.1016/j.stem.2017.11.01610.1016/j.stem.2017.11.016 ↗
22. 10.1016/j.molcel.2016.05.04110.1016/j.molcel.2016.05.041 ↗
23. 10.1016/j.celrep.2017.10.02010.1016/j.celrep.2017.10.020 ↗
24. 10.1126/science.aax446810.1126/science.aax4468 ↗
25. 10.1038/ni.383010.1038/ni.3830 ↗
26. 10.1101/gad.319475.11810.1101/gad.319475.118 ↗
27. 10.1038/s41564-019-0653-910.1038/s41564-019-0653-9 ↗
28. 10.1074/jbc.RA120.01426010.1074/jbc.RA120.014260 ↗
29. 10.1371/journal.ppat.100472610.1371/journal.ppat.1004726 ↗
30. Nagarajan A. · 2019 · 26310.1007/978-1-4939-8808-2_20 ↗